PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Science. Author manuscript; available in PMC Jan 1, 2011.
Published in final edited form as:
PMCID: PMC2917982
NIHMSID: NIHMS223230
Identification of a cell-of-origin for human prostate cancer
Andrew S. Goldstein,1 Jiaoti Huang,2,3,8 Changyong Guo,2,4 Isla P. Garraway,2,4 and Owen N. Witte1,5,6,7,8
1Molecular Biology Institute, University of California, Los Angeles, CA 90095
2Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095
3Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095
4Department of Urology, University of California, Los Angeles, CA 90095
5Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095
6Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095
7Howard Hughes Medical Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095
8Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095
Corresponding Author: Owen N. Witte, M.D., Howard Hughes Medical Institute, University of California, Los Angeles, 675 Charles E. Young Dr. South, 5-748 MRL, Los Angeles, CA 90095-1662, Phone: 310-206-0386, FAX: 310-206-8822, owenwitte/at/mednet.ucla.edu
Abstract
Prostate cancer induced in primary human prostate basal cells recapitulates disease initiation and progression in immunodeficient mice.
Luminal cells are believed to be the cells-of-origin for human prostate cancer because the disease is characterized by luminal cell expansion and absence of basal cells. Yet functional studies addressing the origin of human prostate cancer have not previously been reported due to a lack of relevant in vivo human models. Here we show that basal cells, from primary benign human prostate tissue, can initiate prostate cancer in immunodeficient mice. The cooperative effects of AKT, ERG, and androgen receptor (AR) in basal cells recapitulated the histological and molecular features of human prostate cancer with loss of basal cells and expansion of luminal cells expressing prostate-specific antigen (PSA) and alpha-methylacyl-CoA racemase (AMACR). Our results demonstrate that histological characterization of cancers does not necessarily correlate with the cellular origins of the disease.
Prostate cancer research has been hindered by an absence of model systems in which the disease is initiated from primary human prostate epithelial cells, precluding investigation of transforming alterations and cells-of-origin. Commonly used human prostate cancer cell lines and xenografts were derived from metastatic lesions. Murine prostate cancer models prohibit testing of species-specific therapies such as monoclonal antibodies against human proteins (1). An ideal model system would be human cell-derived and present as a multi-focal disease to accurately represent the heterogeneity of prostate malignancy (2). The system should allow one to investigate the role that specific genetic alterations and paracrine signals play in disease initiation and progression. Finally, the model system should be highly malleable, allowing for comparisons of lesions derived from different cell populations or driven by different genetic alterations. We create such a system by directly transforming naïve adult human prostate epithelium with genetic alterations that are commonly found in human prostate cancer. Activation of the PI3K pathway, typically via loss of PTEN (3), and increased expression of the ETS family transcription factor ERG through chromosomal translocation (4) occur frequently together in human prostate cancer and cooperate to promote disease progression in mice (57). AR is commonly upregulated in human prostate cancer and the androgen signaling axis is implicated in late stage disease (8).
Luminal cells are generally accepted as the cells-of-origin for human prostate cancer (9, 10) because pathologists diagnose the disease based on the absence of basal cell markers (11). Evidence from the mouse implicates both luminal cells (1214) and basal cells (1517) in prostate cancer initiation. While murine cancer cell-of-origin studies typically involve transgenic mice with oncogene expression or Cre-mediated deletion of tumor suppressors driven by cell-type specific promoters (18), parallel studies in the human system require both a method to reliably separate sub-populations of primary cells and an in vivo transformation model.
In addition to rare neuroendocrine cells and reported intermediate phenotypes, the three main epithelial cell populations described in the human prostate are K5 (Keratin 5)+ K14+ K8/18lo basal cells, K5+ K14− K8/18lo basal cells, and K5− K14− K8/18hi luminal cells (19). No commonly accepted strategy exists to isolate such populations from dissociated human prostate tissue. We have previously demonstrated expression of CD49f (integrin alpha 6) and Trop2 (TACSTD2) in human prostate tissue by immunohistochemical staining and flow cytometry, where these two antigens distinguish four separate populations (20, 21). To determine the cellular identities of each population, we performed intracellular flow cytometry for basal (K14) and luminal (K18) keratins on primary human prostate cells in addition to western blot and quantitative PCR (qRT-PCR) analyses on fractions isolated by fluorescence-activated cell sorting (FACS). The CD49floTrop2hi fraction expresses high levels of the luminal keratins K8 and K18, low or negative levels of basal keratins K5 and K14, and high expression of AR and several androgen-regulated genes such as PSA, Nkx3-1 and TMPRSS2 (Fig. 1A–C, fig S1). The CD49fhiTrop2hi fraction expresses high levels of K5 and the basal transcription factor p63, and two discrete peaks for K14 by intracellular flow cytometry, presumably containing both K14+ and K14− basal cells (Fig. 1A–C, fig S1). CD49fhiTrop2hi cells express intermediate levels of the luminal-type keratins (Fig. 1A), confirming previous reports that basal cells express low but detectable levels of K8/18 (19). CD117 (kit) expression is not enriched in either epithelial fraction (fig S1). The results from three different approaches confirm that we can reproducibly enrich for the isolation of basal and luminal epithelial cells from primary human prostate tissue. The remaining cells are negative for both epithelial keratins and gene expression analysis indicates enrichment for CD31+ von Willebrand factor (VWF)+ endothelial cells (CD49fhiTrop2) and CD90+ Vimentin+ stromal cells (CD49floTrop2) (Fig. 1A–C, fig S1).
Fig. 1
Fig. 1
Purification of epithelial cell fractions from primary prostate tissue. (A) FACS plots show the distribution of dissociated primary prostate cells based on expression of CD49f and Trop2 and gates drawn to distinguish four populations. (B) Expression of (more ...)
Classic human epithelial transformation studies involve an initial selection process via immortalization through manipulation with genetic influences like the SV40 T-antigen and/or the catalytic subunit of telomerase in addition to the selected oncogenes (22). We wanted to avoid culture selection by directly transforming primary cells prior to transplantation, so we looked to a recent report by Morrison and colleagues to gain insight into in vivo conditions. Quintana et al. reported that the number of primary human melanoma cells capable of tumor formation could be vastly improved by transplanting primary cells subcutaneously with Matrigel into NOD-SCID-IL2Rγnull (NSG) mice (23). Adapting this strategy, we transduced primary human prostate cells with lentivirus, combined these cells with murine Urogenital Sinus Mesenchyme (UGSM) cells in Matrigel and injected subcutaneously into NSG mice. Starting materials were obtained from patients undergoing radical prostatectomy surgeries and benign tissues were carefully separated from cancer by an experienced Urologic Pathologist. Benign starting materials were negative for expression of human prostate malignancy markers and displayed no features of histologic transformation (fig. S2). Transplantation of cells without genetic modification never resulted in PIN or cancer, demonstrating an absence of malignant cells in starting materials.
We transduced 105 primary human prostate basal or luminal cells with a control lentivirus carrying the fluorescent marker RFP and found that both cell types were capable of lentiviral transduction (fig. S3). We next combined freshly-sorted cells with UGSM in Matrigel and transplanted into NSG mice. Although we were concerned that one cell type might preferentially undergo apoptosis in response to sorting, injection or residence in the subcutaneous space, we found that both cell types survived at relatively equal rates (fig. S4). When grafts were harvested after 8–16 weeks in vivo, outgrowths were only observed from basal cells (Fig. 1D). Luminal-derived grafts lacked epithelial structures and mimicked transplantation of UGSM cells alone (Fig. 1D). Basal-derived prostatic tubules exhibited a remarkable similarity to the native architecture of the gland, demonstrated by an outer K5+ p63+ basal cell layer and one or multiple K8+ AR+ luminal layers (Fig. 1E). As few as 5,000 basal cells were sufficient to generate ducts with distinct basal and luminal layers (table S1). Dissociated cells from grafts recapitulated the original four populations by flow cytometry discerned by expression of Trop2 and CD49f (Fig. 1F). Staining for a human-specific Trop2 antibody confirmed the development of human prostatic tissue (fig. S5). Results were reproducible for four independent patient samples and showed little variation between replicate grafts.
We next introduced a lentivirus carrying both activated (myristoylated) AKT and ERG (7) into primary basal and luminal cells (Fig. 2A). After 8–16 weeks in vivo, we observed the development of abnormal structures expressing AKT, nuclear ERG and the fluorescently linked marker RFP (Fig. 2B, 2D) from primary basal cells but not luminal cells (Fig. 2B). Structures lacking RFP expression, indicating an absence of lentiviral infection, were benign, demonstrating the requirement for expression of oncogenes to initiate a malignant phenotype. We observed an expansion of AR+ luminal-like cells with retention of the p63+ basal layer in basal cell-derived lesions (Fig. 2C). In many areas, cells were positive for both PSA and AMACR (Fig. 2C), a marker of both high grade PIN and prostate cancer (24). Based on the presence of morphologically malignant AR+/PSA+ luminal cells surrounded by p63+ basal cells, basal cell-derived lesions fulfill the histological criteria for the diagnosis of high grade PIN, the precursor lesion to invasive prostate cancer (25).
Fig. 2
Fig. 2
A model of PIN initiated in primary basal cells. (A) Schematic of cell sorting, lentiviral infection (with bicistronic vector encoding activated/myristoylated AKT, ERG and the fluorescent marker RFP) and transplantation to induce initiation of PIN. (B) (more ...)
We evaluated if additional genetic alterations could be used to recapitulate human prostate cancer. Primary cells were transduced with the RFP-marked lentivirus carrying AKT and ERG and a GFP-marked lentivirus carrying AR (26) (Fig. 3A). Combination of AKT, ERG and AR resulted in the development of adenocarcinoma from basal cells (Fig. 3B) but not luminal cells. While some basal cell-derived structures retained expression of p63 and resembled PIN (fig. S6), many glands had lost the basal layer (Fig. 3B, fig. S6), a defining histological feature used by pathologists for the diagnosis of human prostate cancer (11). Cancerous glands expressed PSA (Fig. 3B, fig S7), AR and AMACR (Fig. 3B) in patterns indistinguishable from patient samples of clinical prostate cancer (Fig. 3C). At high power, cells from cancer lesions exhibited hyperchromatic nuclei with visible nucleoli (Fig. 3B–C, H&E insets). Clinical prostate cancer presents as a multifocal disease with considerable heterogeneity of disease grade (2). Within the same grafts, we observed lesions that correspond to benign structures (AR+/PSA+/p63+/AMACR−), PIN (AR+/PSA+/p63+/AMACR+) and cancer (AR+/PSA+/p63−/AMACR+), recapitulating the mixed histology found in cancer patients (fig. S6).
Fig. 3
Fig. 3
A model of prostate cancer initiated in primary basal cells. (A) Schematic of cell sorting, double lentiviral infection (with GFP-encoding AR vector and bicistronic AKT/ERG vector) and transplantation to induce initiation of prostate cancer. (B–C) (more ...)
Cells within the basal fraction can regenerate benign prostate tissue in immunodeficient mice. Introduction of oncogenic alterations in the target cells can induce a disease that mimics human prostate cancer, establishing basal cells as one cell-of-origin for prostate cancer. Our results support studies in the mouse demonstrating that histological characterization of cancers in the absence of functional studies can be misleading for determining cells-of-origin (2730). As the human prostate epithelial hierarchy is further delineated, additional cell-types may be identified with cancer-initiating properties.
Even though basal cells express low levels of AR, they share the property of androgen-independence (31) with late stage castration-resistant prostate cancer cells (8), suggesting that pathways involved in basal cell function and self-renewal may play a role in tumor cell survival and disease recurrence after androgen withdrawal. Therefore, further interrogation of target cells may provide insight into treatments for castration-resistant prostate cancer.
Supplementary Material
Suppl Data
1. Pienta KJ, et al. Prostate. 2008 May 1;68:629. [PMC free article] [PubMed]
2. Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. J Pathol. 1996 Nov;180:295. [PubMed]
3. Yoshimoto M, et al. Cancer Genet Cytogenet. 2006 Sep;169:128. [PubMed]
4. Tomlins SA, et al. Science. 2005 Oct 28;310:644. [PubMed]
5. Carver BS, et al. Nat Genet. 2009 May;41:619. [PMC free article] [PubMed]
6. King JC, et al. Nat Genet. 2009 May;41:524. [PMC free article] [PubMed]
7. Zong Y, et al. Proc Natl Acad Sci U S A. 2009 Jul 28;106:12465. [PubMed]
8. Chen CD, et al. Nat Med. 2004 Jan;10:33. [PubMed]
9. Okada H, et al. Virchows Arch A Pathol Anat Histopathol. 1992;421:157. [PubMed]
10. Parsons JK, Gage WR, Nelson WG, De Marzo AM. Urology. 2001 Oct;58:619. [PubMed]
11. Wojno KJ, Epstein JI. Am J Surg Pathol. 1995 Mar;19:251. [PubMed]
12. Ma X, et al. Cancer Res. 2005 Jul 1;65:5730. [PubMed]
13. Wang X, et al. Nature. 2009 Sep 24;461:495. [PMC free article] [PubMed]
14. Iwata T, et al. PLoS One. 5:e9427. [PMC free article] [PubMed]
15. Lawson DA, et al. Proc Natl Acad Sci U S A. Feb 9;107:2610. [PubMed]
16. Mulholland DJ, et al. Cancer Res. 2009 Nov 15;69:8555. [PMC free article] [PubMed]
17. Wang S, et al. Proc Natl Acad Sci U S A. 2006 Jan 31;103:1480. [PubMed]
18. Barker N, et al. Nature. 2009 Jan 29;457:608. [PubMed]
19. Verhagen AP, et al. Cancer Res. 1992 Nov 15;52:6182. [PubMed]
20. Goldstein AS, et al. Proc Natl Acad Sci U S A. 2008 Dec 30;105:20882. [PubMed]
21. Garraway IP, et al. Prostate. Apr 1;70:491. [PMC free article] [PubMed]
22. Hahn WC, et al. Nature. 1999 Jul 29;400:464. [PubMed]
23. Quintana E, et al. Nature. 2008 Dec 4;456:593. [PMC free article] [PubMed]
24. Wu CL, et al. Hum Pathol. 2004 Aug;35:1008. [PubMed]
25. McNeal JE, Bostwick DG. Hum Pathol. 1986 Jan;17:64. [PubMed]
26. Xin L, et al. Proc Natl Acad Sci U S A. 2006 May 16;103:7789. [PubMed]
27. Youssef KK, et al. Nat Cell Biol. Feb 14;
28. Passegue E, Wagner EF, Weissman IL. Cell. 2004 Oct 29;119:431. [PubMed]
29. So CW, et al. Cancer Cell. 2003 Feb;3:161. [PubMed]
30. Cozzio A, et al. Genes Dev. 2003 Dec 15;17:3029. [PubMed]
31. English HF, Santen RJ, Isaacs JT. Prostate. 1987;11:229. [PubMed]
32. We thank Barbara Anderson for manuscript preparation, Donghui Cheng for cell sorting, Yang Zong for vectors, Hong Zhang for tissue preparation, and Akanksha Chhabra, Ben Van Handel, David Mulholland, Camille Soroudi and Tanya Stoyanova for discussion and technical help. A.S.G. is supported by an institutional Ruth L. Kirschstein National Research Service Award GM07185. J.H. is supported by the American Cancer Society, the DOD Prostate Cancer Research Program, and the UCLA SPORE in Prostate Cancer (Principal Investigator: Rob Reiter). I.P.G is supported by the DOD and the Jean Perkins Foundation. O.N.W. is an Investigator of the Howard Hughes Medical Institute. J.H., I.P.G. and O.N.W. are supported by a Challenge Award from the Prostate Cancer Foundation.